Navigation Links
Zimmer Holdings, Inc. Reports Third Quarter 2012 Financial Results
Date:10/25/2012

WARSAW, Ind., Oct. 25, 2012 /PRNewswire/ --

  • Net Sales of $1,026 million for the third quarter represent a decrease of 0.6% reported (an increase of 2.5% constant currency) from the prior year period
  • Diluted EPS for the third quarter were $1.02 reported, an increase of 1.0% over the prior year period, and $1.15 adjusted, an increase of 10.6% over the prior year period
  • Company updates full-year sales and EPS guidance
  • Zimmer Holdings, Inc. (NYSE and SIX: ZMH) today reported financial results for the quarter ended September 30, 2012.  The Company reported third quarter net sales of $1,026 million, a decrease of 0.6% reported and an increase of 2.5% constant currency over the third quarter of 2011.  Diluted earnings per share for the quarter were $1.02 reported and $1.15 adjusted, an increase of 10.6% adjusted over the prior year period.

    "Zimmer's third quarter performance was highlighted by strong operating margins, as well as above-market sales growth in our Europe, Middle East and Africa business," said David Dvorak, Zimmer President and CEO.  "Our focus continues to be creating value for our stockholders.  We will achieve that goal through the successful commercialization of innovative new products across the portfolio, ongoing progress in our operational excellence programs, and disciplined capital deployment."

    Net earnings for the third quarter were $178.1 million on a reported basis and $202.1 million on an adjusted basis, an increase of 2.5% adjusted over the prior year period.  Operating cash flow for the third quarter was $345.0 million. 

    During the quarter, the Company utilized $97.6 million of cash to acquire 1.56 million shares.  As of September 30, 2012, $1,154.3 million of share repurchase authorization remained available under the current program, which expires on December 31, 2014.

    At the conclusion of the third quarter, Zimmer finalized the acquisition of Dornoch Medical Systems, Inc.  This acquisition enhances Zimmer's surgical products portfolio through the addition of medical waste fluid management and disposal technology.

    Guidance
    The Company updated its revenue and EPS guidance for full-year 2012.  Full-year revenues for 2012 are expected to increase approximately 2% on a constant currency basis from 2011.  Previously, the Company had estimated full-year revenues would increase between approximately 2.5% and 3.5% constant currency.  The Company now estimates that foreign currency translation will decrease revenues by approximately 2% for the full year 2012, resulting in flat revenue growth on a reported basis.  Previously, the Company had estimated foreign currency translation would decrease revenues between approximately 2.0% and 2.5%.  Full-year 2012 diluted earnings per share are projected to be in a range of $4.75 to $4.80 on a reported basis and $5.25 to $5.30 on an adjusted basis.  Prior guidance for full-year 2012 reported and adjusted diluted earnings per share was $4.75 to $4.85 and $5.25 to $5.35, respectively.

    Conference Call
    The Company will conduct its third quarter 2012 investor conference call today, October 25, 2012, at 8:00 a.m. Eastern Time.  The live audio webcast can be accessed via Zimmer's Investor Relations website at http://investor.zimmer.com.  It will be archived for replay following the conference.

    Individuals who wish to dial into the conference call may do so at (888) 878-3901.  International callers should dial (706) 634-9520.  A digital recording will be available two hours after the completion of the conference call from October 25, 2012 to November 8, 2012.  To access the recording, US/Canada callers should dial (855) 859-2056 or (800) 585-8367, or for International callers, dial (404) 537-3406, and enter the conference ID 39798003.

    Sales Tables
    The following tables provide sales results by geographic segment and product category, as well as the percentage change compared to the prior year quarter and nine months on both a reported and constant currency basis.

     NET SALES - THREE MONTHS ENDED SEPTEMBER 30, 2012(in millions, unaudited)ConstantNetReportedCurrencySales % Growth% GrowthGeographic SegmentsAmericas

    $

    584-

    %-

    %Europe246(3)8Asia Pacific196-2Total1,026(1)3Product CategoriesReconstructiveAmericas420(1)(1)Europe191(4)6Asia Pacific145(1)1Total756(2)2KneesAmericas244(4)(4)Europe88(2)9Asia Pacific7524Total407(2)1HipsAmericas14622Europe96(8)3Asia Pacific67(4)(2)Total309(2)2Extremities401012Dental55(1)3Trauma74811Spine50(10)(7)Surgical and other91911NET SALES - NINE MONTHS ENDED SEPTEMBER 30, 2012(in millions, unaudited)ConstantNetReportedCurrencySales % Growth% GrowthGeographic SegmentsAmericas

    $

    1,8321

    %1

    %Europe852(3)5Asia Pacific60733Total3,291-2Product CategoriesReconstructiveAmericas1,336--Europe670(3)4Asia Pacific45344Total2,459-2KneesAmericas787(1)(1)Europe323(3)4Asia Pacific22956Total1,339(1)1HipsAmericas45111Europe326(4)4Asia Pacific21632Total993-2Extremities12768-Dental176(4)(2)Trauma22479Spine155(8)(6)Surgical and other27789About the CompanyFounded in 1927 and headquartered in Warsaw, Indiana, Zimmer designs, develops, manufactures and markets orthopaedic reconstructive, spinal and trauma devices, dental implants, and related surgical products.  Zimmer has operations in more than 25 countries around the world and sells products in more than 100 countries.  Zimmer's 2011 sales were approximately $4.5 billion.  The Company is supported by the efforts of more than 8,500 employees worldwide.

    Website InformationWe routinely post important information for investors on our website, www.zimmer.com, in the "Investor Relations" section. We use this website as a means of disclosing material, non-public information and for complying with our disclosure obligations under Regulation FD. Accordingly, investors should monitor the Investor Relations section of our website, in addition to following our press releases, SEC filings, public conference calls, presentations and webcasts. The information contained on, or that may be accessed through, our website is not incorporated by reference into, and is not a part of, this document.

    Note on Non-GAAP Financial Measures As used in this press release, the term "adjusted" refers to operating performance measures that exclude inventory step-up, the provision for certain Durom® Acetabular Component product claims, special items and certain tax adjustments.  Included in special items are acquisition and integration costs as well as employee termination benefits, consulting and professional fees, certain litigation matters, dedicated personnel expenses, certain contract terminations and asset impairment charges connected with global restructuring and transformation initiatives.  The term "constant currency" refers to any financial measure that excludes the effect of changes in foreign currency exchange rates.  Reconciliations of these non-GAAP measures to the most directly comparable GAAP measure are included in this press release.

    Zimmer Safe Harbor StatementThis press release contains forward-looking statements within the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 based on current expectations, estimates, forecasts and projections about the orthopaedics industry, management's beliefs and assumptions made by management. Forward-looking statements may be identified by the use of forward-looking terms such as "may," "will," "expects," "believes," "anticipates," "plans," "estimates," "projects," "assumes," "guides," "targets," "forecasts," and "seeks" or the negative of such terms or other variations on such terms or comparable terminology. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that could cause actual outcomes and results to differ materially. These risks and uncertainties include, but are not limited to, the success of our quality and operational improvement initiatives; the outcome of the investigation by the U.S. government into Foreign Corrupt Practices Act matters announced in October 2007; price and product competition; changes in customer demand for our products and services caused by demographic changes or other factors; dependence on new product development, technological advances and innovation; shifts in the product category or regional sales mix of our products and services; supply and prices of raw materials and products; control of costs and expenses; our ability to obtain and maintain adequate intellectual property protection; our ability to successfully integrate acquired businesses; our ability to form and implement alliances; challenges relating to changes in and compliance with governmental laws and regulations affecting our U.S. and international businesses, including regulations of the U.S. Food and Drug Administration and foreign government regulators; changes in tax obligations arising from tax reform measures or examinations by tax authorities; product liability and intellectual property litigation losses; the impact of health care reform measures in the U.S. including the impact of the new excise tax on medical devices, reductions in reimbursement levels from third-party payors and cost-containment efforts of health care purchasing organizations; our ability to retain the independent agents and distributors who market our products; and changes in general industry and market conditions, including domestic and international growth rates and general domestic and international economic conditions, including interest rate and currency exchange rate fluctuations. For a further list and description of such risks and uncertainties, see our periodic reports filed with the U.S. Securities and Exchange Commission. We disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be set forth in our periodic reports. Readers of this document are cautioned not to place undue reliance on these forward-looking statements, since, while we believe the assumptions on which the forward-looking statements are based are reasonable, there can be no assurance that these forward-looking statements will prove to be accurate. This cautionary statement is applicable to all forward-looking statements contained in this document. ZIMMER HOLDINGS, INC.  CONSOLIDATED STATEMENTS OF EARNINGS  FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2012 and 2011  (in millions, except per share amounts, unaudited) 20122011% Inc/(Dec) Net Sales $
    ,025.5$
    ,031.5(1)

    % Cost of products sold 

    255.7251.92 Gross Profit 769.8779.6(1) Research and development 

    53.561.0(12) Selling, general and administrative 

    430.0444.0(3) Special items 

    36.98.0366Operating expenses 

    520.4513.01 Operating Profit 249.4266.6(6) Interest income 

    3.81.3203 Interest expense 

    (18.3)(13.0)40 Earnings before income taxes234.9254.9(8) Provision for income taxes 

    57.263.7(10) Net earnings 

    177.7191.2(7) Less:  Net loss attributable to noncontrolling interest 

    (0.4)(0.3)15 Net Earnings of Zimmer Holdings, Inc. $
    78.1
    $
    91.5
    (7) Earnings Per Common Share Basic 

    $
    .02$
    .02-Diluted 

    $
    .02$
    .011 Weighted Average Common Shares Outstanding Basic 

    174.1187.7Diluted 

    175.3188.8 Cash dividends declared per common share 

    $
    .18-100 Certain amounts in the 2011 consolidated statement of earnings have been reclassified to conform  to the 2012 presentation.   ZIMMER HOLDINGS, INC.  CONSOLIDATED STATEMENTS OF EARNINGS  FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2012 and 2011  (in millions, except per share amounts, unaudited) 20122011% Inc/(Dec) Net Sales $
    3,291.2$
    3,284.50

    % Cost of products sold 

    826.3818.81 Gross Profit 2,464.92,465.7(0) Research and development 

    170.3173.5(2) Selling, general and administrative 

    1,346.61,372.3(2) Certain claims 

    -50.0(100) Special items 

    101.147.0115Operating expenses 

    1,618.01,642.8(2) Operating Profit 846.9822.93 Interest income 

    10.76.662 Interest expense 

    (54.0)(39.1)38 Earnings before income taxes803.6790.42 Provision for income taxes 

    203.0186.59 Net earnings 

    600.6603.9(1) Less:  Net loss attributable to noncontrolling interest 

    (1.6)(0.3)397 Net Earnings of Zimmer Holdings, Inc. $
    2.2
    $
    4.2
    (0) Earnings Per Common Share Basic 

    $
    3.43$
    3.178Diluted 

    $
    3.41$
    3.158 Weighted Average Common Shares Outstanding Basic 

    175.6190.6Diluted 

    176.7191.8 Cash dividends declared per common share 

    $
    .36-100 Certain amounts in the 2011 consolidated statement of earnings have been reclassified to conform  to the 2012 presentation.   ZIMMER HOLDINGS, INC.  CONDENSED CONSOLIDATED BALANCE SHEETS  (in millions, unaudited)  September 30,  December 31, 20122011 Assets  Current Assets: Cash and cash equivalents $
    801.5

    $
    768.3Short-term investments 687.4

    455.5Receivables, net 874.9

    838.8Inventories 994.1

    929.8Other current assets 274.0

    284.2Total current assets 3,631.9

    3,276.6 Property, plant and equipment, net 1,185.6

    1,207.3 Goodwill 2,648.6

    2,626.0 Intangible assets, net 760.5

    798.5 Other assets 557.5

    606.9 Total Assets $
    8,784.1

    $
    8,515.3
     Liabilities and Stockholders' Equity  Current liabilities $
    755.2

    $
    723.8 Short-term debt 0.3

    143.3 Other long-term liabilities 463.6

    557.4 Long-term debt 1,734.1

    1,576.0 Stockholders' equity 5,830.9

    5,514.8 Total Liabilities and Stockholders' Equity $
    8,784.1

    $
    8,515.3
      ZIMMER HOLDINGS, INC.  CONSOLIDATED STATEMENTS OF CASH FLOWS  FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2012 and 2011  (in millions, unaudited) 20122011 Cash flows provided by (used in) operating activities  Net earnings $
    .6

    $
    3.9 Depreciation and amortization 272.9

    265.6 Share-based compensation 41.7

    46.1 Income tax benefits from employee stock compensation plans 10.0

    10.6 Excess income tax benefits from employee stock compensation plans (2.3)

    (4.0) Inventory step-up 2.5

    9.6 Changes in operating assets and liabilities, net of acquired assets and liabilities Income taxes 29.7

    6.8Receivables (34.2)

    (39.7)Inventories (53.3)

    (27.7)Accounts payable and accrued expenses 4.0

    (41.3)Other assets and liabilities (87.7)

    (46.1) Net cash provided by operating activities 783.9

    783.8 Cash flows provided by (used in) investing activities  Additions to instruments (104.7)

    (128.9) Additions to other property, plant and equipment (71.4)

    (67.8) Purchases of investments (801.7)

    (403.8) Sales of investments 667.1

    225.0 Investments in other assets (56.8)

    (35.6) Net cash used in investing activities (367.5)

    (411.1) Cash flows provided by (used in) financing activities  Net proceeds under revolving credit facilities (149.9)

    375.2 Proceeds from term loans 147.3

    - Dividends paid to stockholders (63.2)

    - Proceeds from employee stock compensation plans 34.1

    34.0 Excess income tax benefits from employee stock compensation plans 2.3

    4.0 Debt issuance costs (3.3)

    - Repurchase of common stock (345.7)

    (906.5) Net cash used in financing activities (378.4)

    (493.3) Effect of exchange rates on cash and cash equivalents (4.8)

    4.7 Increase (decrease) in cash and cash equivalents 33.2

    (115.9) Cash and cash equivalents, beginning of period 768.3

    668.9 Cash and cash equivalents, end of period $
    801.5

    $
    553.0
     ZIMMER HOLDINGS, INC.  NET SALES BY GEOGRAPHIC SEGMENT  FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2012 and 2011  (in millions, unaudited)  Three Months Ended September 30,  Nine Months Ended September 30, 20122011% Inc/(Dec)20122011% Inc/(Dec) Americas 

    $
    583.5

    $
    582.1

    -

    %

    $   1,832.2

    $   1,820.4

    1

    % Europe 

    245.6

    252.5

    (3)851.6

    876.4

    (3) Asia Pacific 

    196.4

    196.9

    -607.4

    587.7

    3 Total 

    $   1,025.5

    $   1,031.5

    (1)$   3,291.2

    $   3,284.5

    - ZIMMER HOLDINGS, INC.  NET SALES BY PRODUCT CATEGORY  FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2012 and 2011  (in millions, unaudited)  Three Months Ended September 30,  Nine Months Ended September 30, 20122011% Inc/(Dec)20122011% Inc/(Dec) Reconstructive  Knees 

    $
    407.4

    $
    416.7

    (2)

    %

    $   1,338.7

    $   1,349.8

    (1)

    % Hips 

    308.5

    315.6

    (2)993.0

    997.9

    - Extremities 

    39.7

    36.0

    10127.0

    119.6

    6755.6

    768.3

    (2)2,458.7

    2,467.3

    - Dental 

    54.7

    55.1

    (1)176.4

    184.6

    (4) Trauma 

    74.5

    69.3

    8223.9

    208.5

    7 Spine 

    49.8

    55.2

    (10)155.4

    168.5

    (8) Surgical and other 

    90.9

    83.6

    9276.8

    255.6

    8 Total 

    $   1,025.5

    $   1,031.5

    (1)$   3,291.2

    $   3,284.5

     ZIMMER HOLDINGS, INC.RECONCILIATION OF REPORTED % GROWTH TOCONSTANT CURRENCY % GROWTH(unaudited)For the Three Months EndedSeptember 30, 2012ForeignConstantReportedExchangeCurrency% GrowthImpact% GrowthGeographic SegmentsAmericas

    -

    %-

    %-

    %Europe

    (3)(11)8Asia Pacific

    -(2)2Total

    (1)(4)3Product CategoriesReconstructiveAmericas

    (1)-(1)Europe

    (4)(10)6Asia Pacific

    (1)(2)1Total

    (2)(4)2KneesAmericas

    (4)-(4)Europe

    (2)(11)9Asia Pacific

    2(2)4Total

    (2)(3)1HipsAmericas

    2-2Europe

    (8)(11)3Asia Pacific

    (4)(2)(2)Total

    (2)(4)2Extremities10(2)12Dental(1)(4)3Trauma8(3)11Spine(10)(3)(7)Surgical and other9(2)11ZIMMER HOLDINGS, INC.RECONCILIATION OF REPORTED % GROWTH TOCONSTANT CURRENCY % GROWTH(unaudited)For the Nine Months EndedSeptember 30, 2012ForeignConstantReportedExchangeCurrency% GrowthImpact% GrowthGeographic SegmentsAmericas

    1

    %-

    %1

    %Europe

    (3)(8)5Asia Pacific

    3-3Total

    -(2)2Product CategoriesReconstructiveAmericas

    ---Europe

    (3)(7)4Asia Pacific

    4-4Total

    -(2)2KneesAmericas

    (1)-(1)Europe

    (3)(7)4Asia Pacific

    5(1)6Total

    (1)(2)1HipsAmericas

    1-1Europe

    (4)(8)4Asia Pacific

    312Total

    -(2)2Extremities6(2)8Dental(4)(2)(2)Trauma7(2)9Spine(8)(2)(6)Surgical and other8(1)9 ZIMMER HOLDINGS, INC.  Reconciliation of Net Earnings and Adjusted Net Earnings  For the Three Months Ended September 30, 2012 and 2011  (in millions, unaudited)  Three Months  Ended September 30, 20122011 Net Earnings of Zimmer Holdings, Inc. 

    $
    78.1$
    91.5 Inventory step-up 

    0.51.8 Special items 36.98.0 Taxes on inventory step-up and special items* 

    (13.4)(4.1) Adjusted Net Earnings 

    $
    202.1
    $
    97.2
     * The tax effect is calculated based upon the statutory rates for the jurisdictions where the items were incurred.  ZIMMER HOLDINGS, INC.  Reconciliation of Net Earnings and Adjusted Net Earnings  For the Nine Months Ended September 30, 2012 and 2011  (in millions, unaudited)  Nine Months  Ended September 30, 20122011 Net Earnings of Zimmer Holdings, Inc. 

    $
    2.2$
    4.2 Inventory step-up 

    2.59.6 Certain claims -50.0 Special items 101.147.0 Taxes on inventory step-up, certain claims and special items and tax adjustments related to resolution of certain tax matters* 

    (36.8)(50.2) Adjusted Net Earnings 

    $
    9.0
    $
    .6
     * The tax effect is calculated based upon the statutory rates for the jurisdictions where the items were incurred.  

      ZIMMER HOLDINGS, INC.  Reconciliation of Diluted EPS and Adjusted Diluted EPS  For the Three Months Ended September 30, 2012 and 2011  (unaudited)  Three Months  Ended September 30,20122011 Diluted EPS 

    $
    .02$
    .01 Inventory step-up 

    -0.01 Special items 

    0.210.04 Taxes on inventory step-up and special items* 

    (0.08)(0.02) Adjusted Diluted EPS 

    $
    .15
    $
    .04
     * The tax effect is calculated based upon the statutory rates for the jurisdictions where the items were incurred.  ZIMMER HOLDINGS, INC.  Reconciliation of Diluted EPS and Adjusted Diluted EPS  For the Nine Months Ended September 30, 2012 and 2011  (unaudited)  Nine Months  Ended September 30,20122011 Diluted EPS 

    $
    3.41$
    3.15 Inventory step-up 

    0.010.05 Certain claims 

    -0.26 Special items 

    0.580.24 Taxes on inventory step-up, certain claims and special items and tax adjustments related to resolution of certain tax matters* 

    (0.21)(0.26) Adjusted Diluted EPS 

    $
    3.79
    $
    3.44
     * The tax effect is calculated based upon the statutory rates for the jurisdictions where the items were incurred.  ZIMMER HOLDINGS, INC.  Reconciliation of 2012 Projected Diluted EPS and Projected Adjusted Diluted EPS  (unaudited)  Projected Year Ended December 31, 2012: LowHigh Diluted EPS 

    4.754.80 Inventory step-up 

    0.010.01 Special items 

    0.770.77 Taxes on inventory step-up and special items* 

    (0.28)(0.28) Adjusted Diluted EPS 

    $
    5.25
    $
    5.30
     * The tax effect is calculated based upon the statutory rates for the jurisdictions where the items have been or are projected to be incurred.  

     


    '/>"/>
    SOURCE Zimmer Holdings, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved


    Related medicine technology :

    1. Cook Medical, Zimmer, Pro-Dex & J&J to Share Innovative Social Media Approaches to Marketing Device Products in Minneapolis
    2. Zimmer Announces Quarterly Dividend for Second Quarter of 2012
    3. Zimmer Introduces First Porous Metal Interbody Implant for Lumbar Spine in the United States
    4. Zimmer Holdings Announces Live Audio Webcast and Conference Call of Second Quarter 2012 Results
    5. Zimmer Holdings Names Christopher Begley to Board of Directors
    6. Zimmer Holdings to Present at Morgan Stanley 2012 Global Healthcare Conference
    7. China Pharma Holdings, Inc. Reports First Quarter 2012 Financial Results
    8. InfuSystem Holdings, Inc. To Announce First Quarter 2012 Financial Results On May 21, 2012
    9. InfuSystem Holdings, Inc. Receives Letter From NYSE MKT Regarding Timely Notice Of Record Date For 2012 Annual Meeting Of Stockholders
    10. InfuSystem Holdings, Inc. Reports $14.3 Million of Revenues And $1.6 Million Of EBITDA For The First Quarter Of 2012
    11. InfuSystem Holdings, Inc. Terminates "Poison Pill" Plan
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/2/2016)... , Dec. 2, 2016 The U.S. Food ... Jardiance (empagliflozin) to reduce the risk of cardiovascular death ... cardiovascular disease. "Cardiovascular disease is a ... diabetes mellitus," said Jean-Marc Guettier , M.D., C.M., ... in FDA,s Center for Drug Evaluation and Research. "Availability ...
    (Date:12/2/2016)... 2, 2016 Persistence Market Research ... its upcoming report titled, "Global Market Study on Cardiac Pacemaker: ... of -1.4% between 2016 and 2024". The global cardiac pacemaker ... and this is likely to decline to US$ 3923.8 ... cardiac pacemaker market is anticipated to exhibit a declining ...
    (Date:12/2/2016)... NEW YORK , December 2, 2016 ... Market Research titled "Global Market Study on Automated Endoscope Reprocessors: ... Register a CAGR of 8.6% Between 2016 and 2024 " the ... 2015 and is expected to expand at a CAGR of ... market valuation of US$ 1,367.6 Mn by 2024. ...
    Breaking Medicine Technology:
    (Date:12/4/2016)... ... December 02, 2016 , ... Metabolic ... access to nutraceuticals and help doctors more efficiently manage their practice. Power2Practice ... management software platform for Integrative and Functional Medicine. , The Metabolic Code ...
    (Date:12/4/2016)... ... December 03, 2016 , ... "Perfect Harmony ... more tools allowing FCPX editors to create professional looking video in a matter ... Perfect Harmony contains a beautifully designed 3D environment for placing in personal media. ...
    (Date:12/4/2016)... ... December 03, 2016 , ... ... "Best Surgical Body Shaping" at the 2016 Anti-Aging & Beauty Awards ... , The Aesthetic & Anti-Aging Medicine European Congress (AMEC) brings together ...
    (Date:12/4/2016)... ... December 04, 2016 , ... "Pro3rd Displace is a set ... unique displacement design elements," said Christina Austin - CEO of Pixel Film Studios. ... variety of design styles that include both left aligned and right aligned options ...
    (Date:12/4/2016)... ... December 04, 2016 , ... Are You Concerned About Mold ... certified and experienced Indoor Air Quality Companies in VA, MD and DC, recently completed ... , The new mold law in the district of Columbia is a good ...
    Breaking Medicine News(10 mins):